Health Industry News Roundup: Profit Forecasts and Innovations

The health industry sees various highlights: Biogen's raised profit predictions, Mettler-Toledo's upbeat forecast, Heartflow's IPO plans, artificial sweeteners affecting immunotherapy, Trump's price-cutting pressure on pharma firms, UnitedHealth's new CFO, Cigna's strong quarter, and Neuralink's clinical brain chip study in Great Britain.

Biogen has raised its annual profit predictions, buoyed by demand for its rare disease drugs despite lagging sales of its older multiple sclerosis treatments. Notably, Biogen exceeded sales estimates for its Alzheimer's drug Leqembi, indicating improved uptake and fueling a share price rise of up to 5.6%.

Mettler-Toledo International reports strong demand for its laboratory instruments, lifting its annual profit forecast. The company's second-quarter results surpass expectations, upping its 2025 profit view to between $42.10 and $42.60 per share, against analyst predictions of $41.60.

Neuralink, Elon Musk's brain-implant firm, is launching a clinical study in Great Britain. The trial explores how its chips could help patients with paralysis control devices through thought, collaborating with notable medical institutions like University College London Hospitals and Newcastle Hospitals.

(With inputs from agencies.)